There is no doubt that Incannex Healthcare Inc (IXHL) ticks all the boxes.

With 32.22 million shares changed hands, the volume of the stock remained lighter than its average volume of 111.37 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.404 whereas the lowest price it dropped to was $0.3714. The 52-week range on IXHL shows that it touched its highest point at $3.12 and its lowest point at $0.08 during that stretch. Beta for the stock currently stands at 2.67.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IXHL was down-trending over the past week, with a drop of -14.00%, but this was up by 2.70% over a month. Three-month performance surged to 41.56% while six-month performance fell -78.85%. The stock lost -82.07% in the past year, while it has lost -80.31% so far this year. A look at the trailing 12-month EPS for IXHL yields -1.25 with Next year EPS estimates of -1.56. For the next quarter, that number is -0.29. This implies an EPS growth rate of 16.52% for this year and -62.50% for next year.

Float and Shares Shorts:

At present, 93.70 million IXHL shares are outstanding with a float of 73.14 million shares on hand for trading. On 2025-07-31, short shares totaled 7.21 million, which was 769.0 higher than short shares on 1751241600. In addition to Mr. Joel Bradley Latham as the firm’s President, CEO & Executive Director, Mr. Joseph Swan serves as its CFO, Treasurer & Secretary.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, IXHL reported revenue of $0.0 and operating income of -$4582000.0. The EBITDA in the recently reported quarter was -$4707000.0 and diluted EPS was -$0.2.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.03458 being high and -$2.03458 being low. For IXHL, this leads to a yearly average estimate of -$2.03458.

Sete News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.